Correspondence: The First Biosimilar for Biologics in Allergy: CT ‐ P39 (Omlyclo‐Omalizumab‐Igec) Is Available for Asthma, Chronic Spontaneous Urticaria, and Chronic Rhinosinusitis With Nasal Polyps

2026/04/25 by Ludger Klimek, Joaquim Mullol, Sietze Reitsma +22 · 1 voice
Immunology and Microbiology · Medicine · #Allergic Rhinitis and Sensitization #Biosimilars and Bioanalytical Methods #Drug-Induced Adverse Reactions

paper · doi:10.1111/all.70366

openalex publication_date 2026/04/25 · openalex created_date 2026/04/26 · openalex updated_date 2026/07/22

Abstract

Data sharing not applicable to this article as no datasets were generated or analysed during the current study.

Discussions

• L.Klimek, J.Mullol, S.Reitsma, et al., “Correspondence: The First Biosimilar for Biologics in Allergy: CT-P39 (Omlyclo-Omalizumab-Igec) Is Available for Asthma, Chronic Spontaneous #Urticaria, and Chr [bsky, 0 points, 0 comments]

Related

• Management of Patients With Allergic Diseases in the Era of Biologics
• EUFOREA consensus on biologics for CRSwNP with or without asthma
• Omalizumab for the Treatment of Chronic Idiopathic or Spontaneous Urticaria
• An Immunologic Perspective on Adverse Reactions Observed Upon Systemic Therapies of Atopic Dermatitis: A Retrospective Study of 145 Cases
• Real-life evaluation of the effectiveness of biologics for chronic rhinosinusitis with nasal polyps in Europe: a Delphi study to define key variables for the INVENT registry